Dr. Sidhu joined the Donnelly Centre at the University of Toronto in 2008 after ten years as a principal investigator in the Department of Protein Engineering at Genentech, Inc. Genentech is the leading biotechnology company in the world and is renowned for developing technologies that have enabled the success of antibody drugs in oncology. Within this competitive and innovative environment, the Sidhu lab was at the forefront of new technology development and Dr. Sidhu was personally responsible for leading the development of phage-displayed synthetic antibody libraries. Thus Dr. Sidhu has extensive biotechnology experience and concomitant expertise in commercialization of new reagents and technologies.


​Dr. Shenoy has served as R&D Director of Molecular Biology and Biochemistry at Roche developing DNA sequencing workflow for several long read (up to 1kb), high accuracy DNA (Q20 of 800 b) sequencing platforms (GS-FLX Titanium, Plus and Junior series).  He was also involved as Group Leader of Gene Expression Analysis, and Director of R&D Protein Manufacturing that produced an antibody drug conjugate (ADC) currently in Phase II clinical trials for use in triple negative (ER/PR minus, Her2 minus, GPNMB positive) breast cancers. Dr. Shenoy has an impeccable publication record in several top ranking journals and patents to his credit.